7 Healthcare AI Stocks Under $50 With Huge Upside Potential

"Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful multi-year execution path can plausibly deliver triple-digit returns. The $50 ceiling is the filter; the AI flywheel is the thesis."

"Tempus AI ( NASDAQ: TEM | TEM Price Prediction) pairs genomic diagnostics with a massive healthcare data library that pharma partners license for AI-driven drug discovery. At around $43.93, shares are down 25.6% year to date and are well below the $67.20 analyst target price, with 10 Buy or Strong Buy ratings against one Sell. Q4 2025 revenue grew 83% year over year to $367.21 million, adjusted EBITDA flipped positive at $12.89 million, and 2026 guidance calls for $1.59 billion in revenue and roughly $65 million in adjusted EBITDA."

"CEO Eric Lefkofsky said "network effects from our investments in AI continue to compound," backed by deepening partnerships with Gilead, Merck, and Daiichi Sankyo. The risk is that an accumulated deficit of $2.4 billion, heavy stock-based comp, and the $460 million in convertible notes priced in May 2026 add dilution and execution risk. Still, the data flywheel keeps spinning."

"Hims & Hers Health ( NYSE: HIMS) runs a direct-to-consumer telehealth platform that uses AI to personalize care across weight loss, dermatology, mental health, and sexual wellness. At about $25.05 a share, the stock is down 57.2% over one year, with a forward P/E near 48x. FY2026 guidance was raised to $2.80 billion to $3.00 billion in revenue and $275 million to $350 million in adjusted EBITDA, and m"

Healthcare AI stocks have fallen sharply in 2026 despite continued platform maturation. The setup is framed as a valuation dislocation where share prices drop more than underlying product progress. The screening approach emphasizes real revenue, real partnerships, and sufficiently low prices to support a plausible multi-year execution path toward triple-digit returns. Tempus AI is highlighted for genomic diagnostics paired with a large healthcare data library licensed by pharma for AI-driven drug discovery, alongside strong recent revenue growth and improving adjusted EBITDA. Hims & Hers Health is highlighted for an AI-enabled direct-to-consumer telehealth platform with raised FY2026 revenue and adjusted EBITDA guidance, despite valuation and execution risks.

Read at 24/7 Wall St.